Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
A tailored viro-immunotherapy combination approach for the treatment of BRCA1/2 mutated breast and ovarian cancers
FY 2018-19
Summary
BRCA1 and BRCA2 are tumour suppressor genes, both playing essential roles in the DNA repair pathway. Loss of function in either may lead to genetic instability of cells, ultimately leading to malignancy. Alterations (mutations) in either contribute the greatest risk factor for developing breast or ovarian cancer. These cancers tend to be difficult to treat as many do not respond to conventional therapy, while others develop resistance over time. The treatment of BRCA1/2 mutated breast and ovarian cancers with DNA repair inhibitors (commonly known as PARPi) has initially led to promising outcomes. Oral PARPi treatment can selectively kill BRCA1/2 mutated cancer cells through a combination effect targeting the DNA repair pathway. Unfortunately, this treatment is not successful in all patients. Various mechanisms for PARPi resistance have been shown, including restoration of BRCA1/2 function due to differences in the genetic make-up of tumour cells or additional alternations in the BRCA1/2 genes. Oncolytic or “cancer-killing” viruses are an innovative approach to treating even the most complex cancers. Oncolytic viruses target and destroy cancer cells, leaving normal cells unharmed, all while activating a patient’s own immune system to fight the cancer. The aim of this project is (1) to engineer cancer specific viruses targeting the BRCA1/2 genes, (2) evaluate the combination effect of these engineered BRCA1/2 targeting viruses with PARPi, and finally (3) complete a pre-clinical evaluation of BRCA1/2 targeting viruses with PARPi therapy including safety and efficacy using a variety of mouse models. The goal of this project is to develop a combination therapy that can overcome drug resistance and lead to curative treatment for patients with BRCA1/2 mutated cancers.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
406725
Name
Jamieson-Datzkiw Taylor R
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A tailored viro-immunotherapy combination approach for the treatment of BRCA1/2 mutated breast and ovarian cancers
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Immunotherapy; Microrna; Oncolytic Virus; Ovarian Cancer; Rhabdovirus; Synthetic Lethality
Abstract
BRCA1 and BRCA2 are tumour suppressor genes, both playing essential roles in the DNA repair pathway. Loss of function in either may lead to genetic instability of cells, ultimately leading to malignancy. Alterations (mutations) in either contribute the greatest risk factor for developing breast or ovarian cancer. These cancers tend to be difficult to treat as many do not respond to conventional therapy, while others develop resistance over time. The treatment of BRCA1/2 mutated breast and ovarian cancers with DNA repair inhibitors (commonly known as PARPi) has initially led to promising outcomes. Oral PARPi treatment can selectively kill BRCA1/2 mutated cancer cells through a combination effect targeting the DNA repair pathway. Unfortunately, this treatment is not successful in all patients. Various mechanisms for PARPi resistance have been shown, including restoration of BRCA1/2 function due to differences in the genetic make-up of tumour cells or additional alternations in the BRCA1/2 genes. Oncolytic or “cancer-killing” viruses are an innovative approach to treating even the most complex cancers. Oncolytic viruses target and destroy cancer cells, leaving normal cells unharmed, all while activating a patient’s own immune system to fight the cancer. The aim of this project is (1) to engineer cancer specific viruses targeting the BRCA1/2 genes, (2) evaluate the combination effect of these engineered BRCA1/2 targeting viruses with PARPi, and finally (3) complete a pre-clinical evaluation of BRCA1/2 targeting viruses with PARPi therapy including safety and efficacy using a variety of mouse models. The goal of this project is to develop a combination therapy that can overcome drug resistance and lead to curative treatment for patients with BRCA1/2 mutated cancers.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Jamieson-Datzkiw, Taylor R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~